Health status of White Americans

MemorialCare Miller Children's & Women's Hospital Long Beach Joins Second Phase, Two-Year Cohort of Cherished Futures for Black Moms & Babies

Retrieved on: 
Thursday, February 10, 2022
Income, CLC, Disease, NICU, White House, Mortality, Color, Research, Commit, Education, Multi-system (rail), HASC, Ontario Hospital Association, Awareness, Goal, DNP, European Public Health Alliance, Public health, RN, Infant, Birthcare Center, Woman, View, Alliance, Hospital, 2009 Davis Cup, Physician, Community, Multimedia, NYU Langone Hospital — Long Island, Racism, Health status of White Americans, Health insurance, Medicine, Birth control, Animal, Singleton, Vertex, Black

"The data and the firsthand experiences of Black women prove that this is the time for change in birth equity.

Key Points: 
  • "The data and the firsthand experiences of Black women prove that this is the time for change in birth equity.
  • In LA County, Black women and families continue to disproportionately experience higher rates of infant and maternal mortality and morbidity compared to other ethnic groups.
  • "As a Black woman and an OB/GYN, the issues regarding birth equity resonate deeply," says, Lauren Yu, M.D., laborist, Miller Children's & Women's.
  • About MemorialCare Miller Children's & Women's Hospital Long Beach:
    MemorialCare Miller Children's & Women's Hospital Long Beach provides specialized pediatric care for children and young adults, as well as maternity care for expectant mothers.

HONEYWELL SELECTED BY LOCKHEED MARTIN SIKORSKY-BOEING TO POWER DEFIANT X HELICOPTER IN KEY U.S. ARMY PURSUIT

Retrieved on: 
Thursday, February 10, 2022
Aircraft, NASDAQ, Aerospace, News, Sikorsky UH-60 Black Hawk, Industry, FLRAA, Department of Defense Manned Space Flight Support Office, U.S. Army Information Technology Agency, Lockheed Martin, DEFIANT, Electronics, Army, Military personnel, Army of the United States, Efficiency, H-47, IBM Power Systems, Architecture, Technology, Black Hawk, T55, Safety, Honeywell Aerospace, History, Map, Sikorsky, Airport, Future Long-Range Assault Aircraft, Health status of White Americans, Lockheed, Jet fuel, Honeywell

The HTS7500 enhances mission readiness and exceeds mission power and fuel consumption requirements.

Key Points: 
  • The HTS7500 enhances mission readiness and exceeds mission power and fuel consumption requirements.
  • The new engine comes equipped with a modernized control system, which enables a highly secure flow of engine data.
  • The control system improves operating capabilities, reduces life-cycle costs, and ensures engine health status through its digital thread road map.
  • The Black Hawk was developed in the 1960s and 1970s and was selected by the U.S. Army in 1976.

Medable and CVS Health Announce Collaboration to Expand Clinical Trial Access

Retrieved on: 
Monday, February 7, 2022
Health, FDA, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Industry, Senior, General manager, Pharmacy, Multimedia, Medicine, Science, Awareness, Cohort study, Technology, COVID-19 vaccine, Practitioner, Research, Twitter, Clinical trial, Heart, Pharmacist, Patient, Conditional sentence, Review, NYSE, Population, CVS, CTS, Health, CVS Pharmacy, Nursing, Therapy, Physician, MinuteClinic, Coram, Documentation, App Store (iOS/iPadOS), Partnership, Health human resources, CVS Health, Health status of White Americans, COVID-19, Pharmaceutical industry, Medical device, Medical imaging, CVS Health, Medable, CVS HEALTH, MEDABLE

Medable Inc. and CVS Health (NYSE: CVS) today announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic locations via Medables clinical trials software platform.

Key Points: 
  • Medable Inc. and CVS Health (NYSE: CVS) today announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic locations via Medables clinical trials software platform.
  • Those populations often have limited access to health care, and therefore a greater chance of poor health and lower life expectancy.
  • A diverse CVS Health workforce can also contribute to improving culturally inclusive care delivery and clinical trial services.
  • Since May 2021, CVS Health Clinical Trial Services (CTS) has been working with key stakeholders in the biopharmaceutical industry and across the clinical trial ecosystem to design and deliver innovative approaches to research and real-world evidence generation.

Humana Reports Fourth Quarter 2021 Financial Results; Provides Full Year 2022 Financial Guidance

Retrieved on: 
Wednesday, February 2, 2022
Professional Services, Health, Other Professional Services, Insurance, Other Health, General Health, Health status of White Americans, Private Securities Litigation Reform Act, Government, Risk, Patient, Family, Mortality, CMS, Pharmacy, Failure, Physician, SEC, Judgement, Coronavirus, Medicare Advantage, COVID-19 vaccine, Form, Adoption, U.S. Securities and Exchange Commission, Medicare, COVID-19 testing, Marketing, Population, MA, Information, Health, Privacy, Compliance, Vaccine, Acquisition, Lifting, News, Home, Phrase, Investment, Movement, Security (finance), Quality of life, NYSE, History, Information technology, GAAP, EPS, Star, Risk management, Public relations, Insurance, Health insurance, Bank, Pharmaceutical industry, Financial adviser, COVID-19, Humana

The guidance set forth herein assumes no further change in the fair value of these investments.

Key Points: 
  • The guidance set forth herein assumes no further change in the fair value of these investments.
  • This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The ongoing, heightened uncertainty created by the pandemic precludes any prediction as to the ultimate adverse impact to Humana of COVID-19.
  • More information regarding Humana is available to investors via the Investor Relations page of the companys website at humana.com, including copies of:

Shapa Health Granted a Third Patent Solidifying Its Position in a Behavioral Health & Big Data Platform

Retrieved on: 
Tuesday, February 1, 2022
Health status of White Americans, Conditional sentence, CEO, Diabetes, Silicon, Artificial intelligence, Ecosystem, Behavior, Weight loss, Environment, Telehealth, Health, Hypertension, Duke University, Life, Patent, Big data, Machine learning, Pharmaceutical industry

The third patent continues to diversify Shapa Heath's intellectual property portfolio developed by co-founders Nati Lavi and Dan Ariely, a well-known behavioral economist.

Key Points: 
  • The third patent continues to diversify Shapa Heath's intellectual property portfolio developed by co-founders Nati Lavi and Dan Ariely, a well-known behavioral economist.
  • Shapa continues to expand into indirect feedback models for disease prevention and management to optimize telehealth and chronic disease management.
  • Shapa Health's latest patent will focus on diabetes management and prevention through its blood glucose monitor.
  • Shapa Health's Telehealth 2.0 system optimizes virtual care, engagement, and health management, using artificial intelligence and machine learning.

Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases

Retrieved on: 
Tuesday, February 1, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Health status of White Americans, CEO, III, Patient, Degenerative disease, Pulmonary alveolar proteinosis, Deloitte Technology Fast 500, Zebrafish, RNA transfection, Founder, Biotechnology, PCD, EY, Mark (given name), Respiratory system, Program, Series, Autoimmune disease, Gene, Survival, Severe acute respiratory syndrome coronavirus 2, PAP, Therapy, Primary ciliary dyskinesia, Protein, RNA, LNP, Vaccine, Laureus World Sports Awards

Ethris GmbH , a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (23.3 Million) in a Series B financing round led by Laureus Capital.

Key Points: 
  • Ethris GmbH , a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (23.3 Million) in a Series B financing round led by Laureus Capital.
  • Raising this Series B financing represents an important milestone for Ethris and validates the potential of our proprietary mRNA and LNP delivery platforms and the expert team we have built, said Dr. Carsten Rudolph, CEO of Ethris.
  • I welcome Christian to our executive team and am looking forward to his expertise as we enter the next phase of our growth.
  • We are rapidly advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients lives.

GLIDE: Yemeni Doctor Wins Global Disease Elimination Award to Help Keep the Country Free of Lymphatic Filariasis

Retrieved on: 
Monday, December 13, 2021
Philanthropy, Health, Infectious Diseases, Foundation, Pharmaceutical, Biotechnology, Award, EXPO, Neglected tropical diseases, Lymphatic filariasis, Health, Poverty, World, Onchocerciasis, Polio, Universal health care, World Health Organization, Achievement, The Global Institute for Tomorrow, Bill, Health status of White Americans, Leprosy, Maltese Falcon Society, The Bill, Partnership, Tameem Al-Kubati, LF, Pharmaceutical industry, Medical device, Management, Malaria, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.

Key Points: 
  • Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.
  • The five winners were announced yesterday by the Global Institute for Disease Elimination (GLIDE) during a Universal Health Coverage Day event at EXPO 2020 Dubai.
  • Dr Al-Kubati beat 220 applicants across 44 countries to become the first Yemeni winner of the Falcon Awards.
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

The Global Institute for Disease Elimination awards USD1 million to ground-breaking health projects in endemic countries

Retrieved on: 
Sunday, December 12, 2021
Infectious Diseases, Pharmaceutical, Health, Other Health, Research Institute for Tropical Medicine, Closed-end fund, Award, Government, EXPO, Neglected tropical diseases, Lymphatic filariasis, Tropical medicine, Android, Health, Poverty, World, Medical research, Epidemiology, Medical specialty, Polio, Universal Health Coverage Day, Universal health care, Patient, World Health Organization, Disease, Poliovirus, The Global Institute for Tomorrow, Department, Noguchi Memorial Institute for Medical Research, Bill, Health status of White Americans, Onchocerciasis, Aga Khan University, Florida Department of Health, The Bill, Public health, Division, Assistant, Technology, Pediatric nursing, Pharmaceutical industry, Vaccine, Management, Malaria, Woman, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.

Key Points: 
  • The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.
  • The Falcon Awards will support community-based initiatives by empowering local actors with the tools and financial backing to rid the world of these preventable diseases.
  • For more information on The Falcon Awards for Disease Elimination and the winners, please visit: https://glideae.org/awards
    For photos of the winners, please click here .
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

Huawei iSitePower Intelligent Peak Staggering Practice at China Tower Is Included in GSMA Case Study

Retrieved on: 
Friday, December 17, 2021
Solution, Electricity, US, GSMA, Carbon, Mobile World Congress, Electronics, Time, AI, Temperature, Mobile telephony, SOC, Health status of White Americans, OPEX, Efficiency, Digital, United Regions / Forum of Regional Governments and Global Associations of Regions, China Tower, Renewable energy, Electric battery, Huawei

China Tower Zhejiang Branch and Huawei worked together and used iSitePower AI technologies to implement intelligent peak staggering at base stations, reducing electricity costs by 17.1% per site per year while ensuring reliable backup power.

Key Points: 
  • China Tower Zhejiang Branch and Huawei worked together and used iSitePower AI technologies to implement intelligent peak staggering at base stations, reducing electricity costs by 17.1% per site per year while ensuring reliable backup power.
  • China Tower Zhejiang Branch and Huawei iSitePower launched the intelligent peak staggering technology to improve battery utilization and reduce electricity fees for base stations by leveraging peak-valley tariffs.
  • Intelligent peak staggering can reduce power consumption costs while balancing grid loads, bringing significant economic and social benefits.
  • After intelligent peak staggering is used at sites of China Tower Zhejiang Branch, electricity cost is reduced by US$280 (17.1%) per site per year.

Life Insurance Insurtech Pendella Selected As Top 10 Startup Of 2021

Retrieved on: 
Tuesday, December 14, 2021
Software as a service, Chief executive officer, CIOS, Insurance, Life, Intelligence, Bias, Industry, VCS, Health status of White Americans, Disability, Multimedia, Lemonade, Metromile, Technology, Financial services, Health insurance, Life insurance

FORT MYERS, Fla., Dec. 14, 2021 /PRNewswire/ --Pendella Technologies, a fast-growing technology company on a mission to take the bias out of life insurance, has been named a Top InsurTech Startup of 2021 by Insurance CIO Outlook.

Key Points: 
  • FORT MYERS, Fla., Dec. 14, 2021 /PRNewswire/ --Pendella Technologies, a fast-growing technology company on a mission to take the bias out of life insurance, has been named a Top InsurTech Startup of 2021 by Insurance CIO Outlook.
  • Insurance CIO Outlook presented the winners, which also included prominent insurtechs Lemonade, Next Insurance and MetroMile, in its December issue.
  • Gaydos, an entrepreneur and seasoned expert in the insurance sector, was featured in the December cover story of Insurance CIO Outlook.
  • The CIO Insurance Outlook Insurtech Startup award wraps up an exciting year for Pendella that included new partnerships with several nationwide online retail insurance agencies, and a soon to be announced deal with a major publicly traded insurance broker.